# Testing the Effects of Contingency Management and Behavioral Economics on Buprenorphine-Naloxone Treatment Adherence Using a Sequential Multiple Assignment Randomized Trial (SMART) Design

> **NIH NIH R33** · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2021 · $2,477,571

## Abstract

This application to the RFA-AT-19-006 HEAL Initiative: Behavioral Research to Improve MAT: Behavioral and
Social Interventions to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders
(R61/R33 Clinical Trial Optional) will develop and execute a Sequential Multiple Assignment Randomized Trial
(SMART) Design to test two forms of behavioral economics intervention to promote Medication Assisted
Treatment (MAT) for Opioid Use Disorder. The R61 phase will collect qualitative and quantitative data from
existing buprenorphine-naloxone patients to explore modifiable factors that may impact MAT adherence. This
information will be used to adapt an in person, brief motivational interviewing and substance free activities
intervention (BMI+SFAS) previously developed to reduce binge/problematic drinking and marijuana use. This
BMI+SFAS will be compared with contingency management, one of the most effective forms of psychosocial
treatment for substance use. After the development phase, both forms of intervention will be tested for
satisfaction and acceptability with participants who are initiating buprenorphine-naloxone treatment. Feasibility
of methods will also be assessed during this pilot to identify any issues with execution. The R33 phase of this
application will execute a Sequential Multiple Assignment Randomized Trial (SMART) to test these two
different forms of intervention to promote MAT adherence during the four weeks of treatment initiation, and
throughout the following 6 months of MAT. Adherence to buprenorphine-naloxone will be defined as
attendance at physician visits, a positive urine screen for buprenorphine-naloxone, and prescription drug
monitoring. After the first randomization, we predict that a higher percentage of those in the contingency
management condition will be adherent than those in BMI+SFAS. Those who are adherent throughout the first
4 weeks will continue in their arm of intervention for the next 6 months, but those non-adherent with be re-
randomized to either switch to the other form of intervention or add the other form of intervention. Adherence
will then be assessed again after 6 months of intervention. This innovative design that tests the sequential use
of two psychosocial interventions to increase adherence to MAT initiation is likely to have a significant impact
on engagement of Opioid Use Disorder patients in treatment. The use of a SMART design will test multiple
levels of intervention for individuals who are resistant to MAT adherence, therefore addressing an underserved
population with Opioid Use Disorder.

## Key facts

- **NIH application ID:** 10474683
- **Project number:** 4R33AT010604-02
- **Recipient organization:** UNIVERSITY OF TENNESSEE HEALTH SCI CTR
- **Principal Investigator:** Karen J Derefinko
- **Activity code:** R33 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,477,571
- **Award type:** 4N
- **Project period:** 2019-09-28 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10474683

## Citation

> US National Institutes of Health, RePORTER application 10474683, Testing the Effects of Contingency Management and Behavioral Economics on Buprenorphine-Naloxone Treatment Adherence Using a Sequential Multiple Assignment Randomized Trial (SMART) Design (4R33AT010604-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10474683. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
